Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...

It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...

For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the J ...

against respiratory syncytial virus and human rhinovirus in nasal epithelium in vitro and mice in vivo Overview Prophylactic intranasal RIG-101 demonstrates potent antiviral activities against human ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Respiratory virus data included in the interactive data application is up-to-date as of September 14, 2024. Among its new features, the dashboard now includes RSV Severe Outcomes data.

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

A normal respiratory rate for adults is between 12 to 18 breaths per minute. Normal respiratory rates for children depend on their age, with babies and toddlers taking more breaths per minute.